Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
Stock Summary
Top Correlated Resources
002004.SZ
Top 10 Correlated ETFs
002004.SZ
Top 10 Correlated Stocks
002004.SZ
Financial details
Company Rating
Buy
Market Cap
10.53B
Income
876.87M
Revenue
13.31B
Book val./share
5.19
Cash/share
2.47
Dividend
0.22
Dividend %
4.14%
Employees
12.46K
Optionable
No
Shortable
Yes
Earnings
29 Apr 2022
P/E
12.09
Forward P/E
-
PEG
3.65
P/S
0.79
P/B
1.02
P/C
2.15
P/FCF
81.98
Quick Ratio
0.43
Current Ratio
1.06
Debt / Equity
0.2
LT Debt / Equity
0.13
-
-
EPS (TTM)
0.44
EPS next Y
-
EPS next Q
-
EPS this Y
3.03%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
6.34%
Revenue last 5Y
6.29%
Revenue Q/Q
-2.9%
EPS Q/Q
132.05%
-
-
-
-
SMA20
-10.38%
SMA50
-4.73%
SMA100
6.04%
Inst Own
-
Inst Trans
-
ROA
3%
ROE
8%
ROC
0.12%
Gross Margin
38%
Oper. Margin
17%
Profit Margin
7%
Payout
50%
Shs Outstand
1.98B
Shs Float
1.21B
-
-
-
-
Target Price
-
52W Range
4.54-7.86
52W High
-24%
52W Low
+33%
RSI
30.06
Rel Volume
0.53
Avg Volume
18.22M
Volume
9.59M
Perf Week
-4.83%
Perf Month
-12.64%
Perf Quarter
-10.89%
Perf Half Y
-12.79%
-
-
-
-
Beta
0.469352
-
-
Volatility
0.06%, 0.3%
Prev Close
-0.56%
Price
5.32
Change
-1.66%
Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 4.48 | 5.17 | 5.04 | 5.51 | 6.27 | |
| Net income per share | 0.25 | 0.25 | 0.31 | 0.33 | 0.34 | |
| Operating cash flow per share | 0.29 | 0.93 | 1.04 | 1.2 | 0.64 | |
| Free cash flow per share | -0.19 | 0.4 | 0.32 | 0.58 | 0.01 | |
| Cash per share | 3.79 | 2.13 | 2.02 | 2.52 | 2.75 | |
| Book value per share | 6.54 | 6.23 | 6.62 | 7.16 | 5.13 | |
| Tangible book value per share | 4.04 | 3.78 | 4.16 | 4.57 | 5.41 | |
| Share holders equity per share | 6.54 | 6.23 | 6.62 | 7.16 | 5.13 | |
| Interest debt per share | 5.92 | 5.05 | 4.74 | 4.91 | 4.58 | |
| Market cap | 13.67B | 9.74B | 9.8B | 9.44B | 12.28B | |
| Enterprise value | 17.47B | 15.11B | 15.36B | 14.45B | 16.46B | |
| P/E ratio | 26.92 | 19.04 | 15.81 | 14.48 | 18.32 | |
| Price to sales ratio | 1.5 | 0.92 | 0.97 | 0.87 | 0.99 | |
| POCF ratio | 23.12 | 5.1 | 4.71 | 3.98 | 9.67 | |
| PFCF ratio | -35.86 | 12.03 | 15.11 | 8.27 | 930.91 | |
| P/B Ratio | 1.03 | 0.76 | 0.74 | 0.67 | 1.21 | |
| PTB ratio | 1.03 | 0.76 | 0.74 | 0.67 | 1.21 | |
| EV to sales | 1.92 | 1.43 | 1.52 | 1.33 | 1.33 | |
| Enterprise value over EBITDA | 11.55 | 7.73 | 7.64 | 6.63 | 7.35 | |
| EV to operating cash flow | 29.54 | 7.92 | 7.38 | 6.09 | 12.96 | |
| EV to free cash flow | -45.82 | 18.67 | 23.68 | 12.66 | 1.25K | |
| Earnings yield | 0.04 | 0.05 | 0.06 | 0.07 | 0.05 | |
| Free cash flow yield | -0.03 | 0.08 | 0.07 | 0.12 | 0 | |
| Debt to equity | 0.41 | 0.22 | 0.15 | 0.13 | 0.22 | |
| Debt to assets | 0.54 | 0.52 | 0.5 | 0.5 | 0.47 | |
| Net debt to EBITDA | 2.51 | 2.75 | 2.76 | 2.3 | 1.87 | |
| Current ratio | 1.47 | 1.03 | 0.92 | 0.92 | 1.08 | |
| Interest coverage | 1.75 | 2.36 | 2.81 | 2.78 | 3.52 | |
| Income quality | 1.16 | 3.73 | 3.36 | 3.64 | 1.89 | |
| Dividend Yield | 0.06 | 0.1 | 0.1 | 0.1 | 0.07 | |
| Payout ratio | 1.5 | 1.93 | 1.56 | 1.45 | 1.28 | |
| Sales general and administrative to revenue | 0.03 | 0.03 | 0.04 | 0.04 | 0.03 | |
| Research and developement to revenue | 0.02 | 0.03 | 0.03 | 0.03 | 0.03 | |
| Intangibles to total assets | 0.18 | 0.19 | 0.18 | 0.18 | 0.17 | |
| Capex to operating cash flow | -1.64 | -0.58 | -0.69 | -0.52 | -0.99 | |
| Capex to revenue | -0.11 | -0.1 | -0.14 | -0.11 | -0.1 | |
| Capex to depreciation | -2.51 | -1.87 | -2.36 | -1.77 | -1.68 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 6.07 | 5.92 | 6.8 | 7.29 | 6.26 | |
| ROIC | 0.05 | 0.09 | 0.1 | 0.09 | 0.09 | |
| Return on tangible assets | 0.02 | 0.02 | 0.03 | 0.03 | 0.03 | |
| Graham Net | -3.5 | -4.15 | -4.15 | -4.12 | -3.86 | |
| Working capital | 4.71B | 350.85M | -901.46M | -917.78M | 924.82M | |
| Tangible asset value | 8.2B | 7.72B | 8.32B | 9.03B | 10.65B | |
| Net current asset value | -1.1B | -2.8B | -3.33B | -3.29B | -1.91B | |
| Invested capital | 0.87 | 0.76 | 0.67 | 0.65 | 0.85 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 1.86B | 1.76B | 1.64B | 1.76B | 2.1B | |
| Average inventory | 1.94B | 1.95B | 2.02B | 1.95B | 2.18B | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 115.25 | 102.42 | 103.34 | 99.97 | 117.06 | |
| Days of inventory on hand | 113.94 | 113.3 | 141.52 | 110.9 | 115.29 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 3.17 | 3.56 | 3.53 | 3.65 | 3.12 | |
| Inventory turnover | 3.2 | 3.22 | 2.58 | 3.29 | 3.17 | |
| ROE | 0.04 | 0.04 | 0.05 | 0.05 | 0.07 | |
| Capex per share | -0.48 | -0.54 | -0.72 | -0.62 | -0.64 |
Quarterly Fundamentals Overview
Last date of statement is 2022-06-30 for Q2
| Metric | History | 2021-06-30 | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 1.44 | 1.42 | 1.84 | 1.72 | 1.67 | |
| Net income per share | 0.11 | 0.08 | 0.07 | 0.09 | 0.2 | |
| Operating cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Free cash flow per share | 0.17 | 0 | 0.04 | -0.08 | 0.1 | |
| Cash per share | 2.66 | 2.8 | 2.67 | 2.69 | 2.47 | |
| Book value per share | 6.91 | 7.31 | 4.99 | 5.19 | 5.19 | |
| Tangible book value per share | 4.36 | 4.77 | 5.26 | 5.55 | 5.68 | |
| Share holders equity per share | 6.91 | 7.31 | 4.99 | 5.19 | 5.19 | |
| Interest debt per share | 4.63 | 4.41 | 4.29 | 4.65 | 4.56 | |
| Market cap | 12.59B | 14.07B | 14.67B | 12.13B | 11.04B | |
| Enterprise value | 17.23B | 17.9B | 18.85B | 16.68B | 15.78B | |
| P/E ratio | 13.59 | 20.99 | 24.55 | 17.99 | 7.06 | |
| Price to sales ratio | 4.3 | 4.88 | 3.93 | 3.57 | 3.35 | |
| POCF ratio | 0 | 0 | 0 | 0 | 0 | |
| PFCF ratio | 37.07 | -4.93K | 179.76 | -76.8 | 53.19 | |
| P/B Ratio | 0.9 | 0.95 | 1.45 | 1.18 | 1.07 | |
| PTB ratio | 0.9 | 0.95 | 1.45 | 1.18 | 1.07 | |
| EV to sales | 5.88 | 6.21 | 5.06 | 4.91 | 4.78 | |
| Enterprise value over EBITDA | 42.59 | 51.32 | 42.86 | 39.13 | 23.56 | |
| EV to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| EV to free cash flow | 50.74 | -6.28K | 230.99 | -105.57 | 76.01 | |
| Earnings yield | 0.02 | 0.01 | 0.01 | 0.01 | 0.04 | |
| Free cash flow yield | 0.03 | 0 | 0.01 | -0.01 | 0.02 | |
| Debt to equity | 0.18 | 0.14 | 0.22 | 0.27 | 0.2 | |
| Debt to assets | 0.52 | 0.51 | 0.47 | 0.47 | 0.46 | |
| Net debt to EBITDA | 11.47 | 10.99 | 9.5 | 10.66 | 7.08 | |
| Current ratio | 0.98 | 1.02 | 1.08 | 1.15 | 1.06 | |
| Interest coverage | 3.85 | 2.75 | 4.66 | 4.85 | 7.86 | |
| Income quality | 0 | 0 | 0 | 0 | 0 | |
| Dividend Yield | 0.04 | 0.01 | 0.01 | 0.01 | 0.05 | |
| Payout ratio | 2.28 | 0.78 | 0.72 | 0.62 | 1.38 | |
| Sales general and administrative to revenue | -0.02 | 0.24 | -0.12 | 0.09 | -0.02 | |
| Research and developement to revenue | 0.03 | 0.02 | 0.03 | 0.02 | 0.03 | |
| Intangibles to total assets | 0.18 | 0.17 | 0.17 | 0.17 | 0.17 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | -0.09 | -0.08 | -0.1 | -0.09 | -0.05 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 4.21 | 3.69 | 2.88 | 3.16 | 4.81 | |
| ROIC | 0.02 | 0.02 | 0.03 | 0.02 | 0.04 | |
| Return on tangible assets | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | |
| Graham Net | -4.27 | -4.07 | -3.75 | -3.81 | -3.96 | |
| Working capital | -225.7M | 190.51M | 924.82M | 1.6B | 643.25M | |
| Tangible asset value | 8.83B | 9.67B | 10.65B | 10.98B | 11.24B | |
| Net current asset value | -3.79B | -2.97B | -1.91B | -1.73B | -2.02B | |
| Invested capital | 0.66 | 0.59 | 0.85 | 0.89 | 0.87 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 2.24B | 2.24B | 2.4B | 2.35B | 2.34B | |
| Average inventory | 2.42B | 2.45B | 2.45B | 2.49B | 2.5B | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 115.04 | 104.54 | 93.08 | 99.89 | 108.29 | |
| Days of inventory on hand | 126.56 | 119.15 | 91.67 | 105.78 | 116.79 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0.78 | 0.86 | 0.97 | 0.9 | 0.83 | |
| Inventory turnover | 0.71 | 0.76 | 0.98 | 0.85 | 0.77 | |
| ROE | 0.02 | 0.01 | 0.01 | 0.02 | 0.04 | |
| Capex per share | -0.13 | -0.12 | -0.19 | -0.16 | -0.09 |
Frequently Asked Questions
What is Huapont Life Sciences Co., Ltd. stock symbol ?
Huapont Life Sciences Co., Ltd. is a CN stock and trading under the symbol 002004.SZ
What is Huapont Life Sciences Co., Ltd. stock quote today ?
Huapont Life Sciences Co., Ltd. stock price is $5.32 today.
Is Huapont Life Sciences Co., Ltd. stock public?
Yes, Huapont Life Sciences Co., Ltd. is a publicly traded company.
Company Profile
- Volume Average 18.22M
- Market Capitalization 10.53B
- Employee 12.46K
- Headquarters Chongqing,CN
- IPO Date 2004-06-25
-
Website
https://www.huapont.com.cn 
Huapont Life Sciences Co., Ltd. engages in the pharmaceutical and agrochemical businesses in China and internationally. The company is involved in the production and sale of pharmaceutical preparations and intermediates. It also offers medicines for skin, tuberculosis, anti-infection, respiratory, anti-tumor, and ophthalmology, as well as health management products. In addition, the company provides pesticide technical, intermediate and preparation products, and GLP registration technical services. The company was formerly known as Huapont-Nutrichem Co., Ltd. and changed its name to Huapont Life Sciences Co., Ltd. in September 2015. Huapont Life Sciences Co., Ltd. was founded in 2001 and is based in Chongqing, China. Huapont Life Sciences Co., Ltd. was formerly a subsidiary of Huipont Tourism Co. Ltd.
